Richard Stone, MD, Dana-Farber Cancer Institute, Boston, MA, gives an overview of the key topics that were discussed at a session on risk-adapted therapy for acute myeloid leukemia (AML) that took place at this year’s ISAL meeting. Prof. Stone comments on the promise of targeting CD123, CD47, and TP53. This interview took place at the 18th International Symposium on Acute Leukemias (ISAL XVIII), held in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.